X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (280) 280
male (166) 166
dalteparin (161) 161
dalteparin - pharmacology (147) 147
female (144) 144
index medicus (127) 127
anticoagulants - pharmacology (117) 117
pharmacology & pharmacy (112) 112
enoxaparin (105) 105
anticoagulants - therapeutic use (97) 97
heparin (94) 94
middle aged (89) 89
adult (86) 86
dalteparin - therapeutic use (86) 86
animals (83) 83
molecular-weight heparin (82) 82
unfractionated heparin (81) 81
aged (80) 80
hematology (77) 77
anticoagulants (74) 74
anticoagulants - administration & dosage (72) 72
dalteparin - administration & dosage (68) 68
venous thromboembolism (67) 67
prevention (61) 61
thromboembolism (60) 60
heparin - pharmacology (56) 56
low-molecular-weight heparin (53) 53
thrombosis (52) 52
peripheral vascular disease (50) 50
deep-vein thrombosis (49) 49
heparin, low-molecular-weight - therapeutic use (47) 47
dose-response relationship, drug (46) 46
heparin, low-molecular-weight - pharmacology (45) 45
pharmacokinetics (44) 44
anticoagulants - adverse effects (43) 43
factor xa inhibitors (41) 41
blood coagulation - drug effects (40) 40
aged, 80 and over (38) 38
low molecular weight heparin (37) 37
venous thrombosis - prevention & control (36) 36
rats (35) 35
enoxaparin - pharmacology (34) 34
pregnancy (34) 34
thromboembolism - prevention & control (34) 34
medicine & public health (33) 33
therapy (33) 33
analysis (32) 32
time factors (32) 32
anticoagulants - pharmacokinetics (31) 31
dalteparin - adverse effects (29) 29
dalteparin - pharmacokinetics (29) 29
molecular weight (29) 29
prophylaxis (29) 29
warfarin (29) 29
risk factors (28) 28
drug therapy (27) 27
fibrinolytic agents - pharmacology (27) 27
heparin, low-molecular-weight - administration & dosage (27) 27
enoxaparin - therapeutic use (26) 26
surgery (26) 26
thromboprophylaxis (26) 26
treatment outcome (26) 26
fibrinolytic agents - therapeutic use (25) 25
pharmacology/toxicology (25) 25
anticoagulation (24) 24
venous thromboembolism - prevention & control (24) 24
angiogenesis (23) 23
cardiac & cardiovascular systems (23) 23
thrombin (23) 23
venous thrombosis - drug therapy (23) 23
coagulation (21) 21
dalteparin - chemistry (21) 21
injections, subcutaneous (21) 21
low-molecular-weight (21) 21
oncology (21) 21
venous thrombosis (21) 21
partial thromboplastin time (20) 20
pharmacology (20) 20
research (20) 20
dalteparin-sodium, adverse reactions (19) 19
enoxaparin - administration & dosage (19) 19
heparin - therapeutic use (19) 19
postoperative complications - prevention & control (19) 19
prospective studies (19) 19
retrospective studies (19) 19
cancer (18) 18
dalteparin sodium (18) 18
fondaparinux (18) 18
drug administration schedule (17) 17
health aspects (17) 17
heparin, low-molecular-weight - adverse effects (17) 17
in-vitro (17) 17
standard heparin (17) 17
activation (16) 16
administration, oral (16) 16
cells, cultured (16) 16
dosage and administration (16) 16
elderly (16) 16
factor xa - metabolism (16) 16
plasma (16) 16
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (416) 416
Russian (4) 4
Japanese (2) 2
Spanish (2) 2
Chinese (1) 1
Italian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Clinical Pharmacology, ISSN 0091-2700, 05/2005, Volume 45, Issue 5, pp. 555 - 565
Dabigatran etexilate is an oral low‐molecular‐weight direct thrombin inhibitor. Following oral administration, dabigatran etexilate is rapidly converted to its... 
direct thrombin inhibitor | pharmacokinetics | total hip replacement | Dabigatran etexilate | venous thromboembolism | Total hip replacement | Pharmacokinetics | Venous thromboembolism | Direct thrombin inhibitor | ENOXAPARIN | SURGERY | dabigatran etexilate | MANAGEMENT | PREVENTION | DALTEPARIN | KNEE REPLACEMENT | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | II RANDOMIZED-TRIAL | Area Under Curve | Humans | Middle Aged | Thrombin - antagonists & inhibitors | Pyridines - pharmacokinetics | Male | Metabolic Clearance Rate | Dabigatran | Absorption | Drug Interactions | Aged, 80 and over | Adult | Female | Omeprazole - pharmacology | Sulfoxides - pharmacology | Proton Pump Inhibitors | Administration, Oral | Food-Drug Interactions | Benzimidazoles - pharmacokinetics | Arthroplasty, Replacement, Hip | Cross-Over Studies | 2-Pyridinylmethylsulfinylbenzimidazoles | Benzimidazoles - pharmacology | Aged | Omeprazole - analogs & derivatives | Prevention | Evaluation | Thrombophlebitis | Antithrombins | Research | Thrombin/antagonists & inhibitors | Oral | 80 and over | Surgery | Benzimidazoles/pharmacokinetics/pharmacology | Administration | H(+)-K(+)-Exchanging ATPase/antagonists & inhibitors | Arthroplasty | Replacement | Pyridines/pharmacokinetics | Kirurgi | Hip | Sulfoxides/pharmacology | Omeprazole/analogs & derivatives/pharmacology
Journal Article
Critical Care Medicine, ISSN 0090-3493, 07/2006, Volume 34, Issue 7, pp. 1883 - 1891
OBJECTIVE:To examine whether dalteparin, a low molecular weight heparin, prevents hepatic damage by inhibiting leukocyte activation, we analyzed its effect on... 
Low molecular weight heparin | Ischemia-reperfusion injury | Prostacyclin | Leukocytes | Tumor necrosis factor | Liver injury | liver injury | ACTIVATED PROTEIN-C | prostacyclin | FACTOR-ALPHA PRODUCTION | low molecular weight heparin | PULMONARY VASCULAR INJURY | MICROTHROMBUS FORMATION | HEPATIC ISCHEMIA/REPERFUSION INJURY | LEUKOCYTE | ischemia-reperfusion injury | TUMOR-NECROSIS-FACTOR | tumor necrosis factor | ENDOTHELIAL-CELLS | leukocytes | INHIBITOR | CRITICAL CARE MEDICINE | Propionates - pharmacology | Liver - enzymology | Prospective Studies | Rats, Wistar | Epoprostenol - biosynthesis | Male | Leukocytes - physiology | Nitrobenzenes - pharmacology | Calcium - blood | Interleukin-12 - blood | Dalteparin - therapeutic use | Peroxidase - analysis | Inflammation - drug therapy | Heparin - pharmacology | Dalteparin - pharmacology | Cyclooxygenase 2 Inhibitors - pharmacology | Fibrin Fibrinogen Degradation Products - analysis | Liver Diseases - prevention & control | 6-Ketoprostaglandin F1 alpha - biosynthesis | Rats | Anticoagulants - therapeutic use | Random Allocation | Sulfonamides - pharmacology | Indomethacin - pharmacology | Liver - chemistry | Edema - diagnosis | Naphthalenes - pharmacology | Tumor Necrosis Factor-alpha - analysis | Monocytes - chemistry | Monocytes - enzymology | Liver - blood supply | Animals | Reperfusion Injury - prevention & control | Endothelium - metabolism | Anticoagulants - pharmacology | Transaminases - blood | In Vitro Techniques
Journal Article
Thrombosis Research, ISSN 0049-3848, 2010, Volume 126, Issue 4, pp. e286 - e293
Abstract Introduction Edoxaban (the free base of DU-176b) is a new, oral direct Factor Xa inhibitor. This is the first study to compare the hemostatic response... 
Hematology, Oncology and Palliative Medicine | Edoxaban, ximelagatran, dalteparin | Anticoagulants | Blood coagulation | ATRIAL-FIBRILLATION | ORTHOPEDIC-SURGERY | KNEE REPLACEMENT | VENOUS THROMBOEMBOLISM | PHARMACOKINETICS | TOTAL HIP | ANTITHROMBOTIC THERAPY | ORAL DIRECT THROMBIN | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | GENERATION | HEMATOLOGY | Dalteparin - administration & dosage | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Humans | Pyridines - pharmacokinetics | Male | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Administration, Cutaneous | Azetidines - pharmacology | Thiazoles - therapeutic use | Antithrombins - pharmacokinetics | Benzylamines - administration & dosage | Thiazoles - pharmacokinetics | Antithrombins - pharmacology | Dalteparin - therapeutic use | Female | Pyridines - therapeutic use | Dalteparin - pharmacology | Pyridines - administration & dosage | Administration, Oral | Antithrombins - therapeutic use | Anticoagulants - therapeutic use | Azetidines - pharmacokinetics | Dalteparin - pharmacokinetics | Azetidines - administration & dosage | Azetidines - therapeutic use | Blood Coagulation - drug effects | Anticoagulants - pharmacology | Aged | Anticoagulants - pharmacokinetics | Pyridines - pharmacology | Thiazoles - pharmacology | Thrombosis - drug therapy | Benzylamines - pharmacokinetics | Benzylamines - pharmacology | Benzylamines - therapeutic use | Medical examination | Prothrombin | Thrombin | Comparative analysis | Ximelagatran | Blood
Journal Article
Journal Article
Thrombosis Research, ISSN 0049-3848, 2002, Volume 108, Issue 1, pp. 77 - 84
Introduction: Mounting evidence implies beneficial properties of statins and angiotensin converting enzyme (ACE)-inhibitors beyond those of their original... 
Monocytes | ACE-inhibitors | Cytokines | Statins | Endothelial cells | Tissue factor | REDUCTASE INHIBITORS | monocytes | endothelial cells | CORONARY-ARTERY DISEASE | ATHEROSCLEROTIC PLAQUES | tissue factor | ANGIOTENSIN-II | VASCULAR SMOOTH-MUSCLE | ADHESION | IN-VITRO | statins | PERIPHERAL VASCULAR DISEASE | cytokines | CHEMOATTRACTANT PROTEIN-1 | SIMVASTATIN | HEMATOLOGY | COCULTURES | Tumor Necrosis Factor-alpha - metabolism | Dalteparin - pharmacology | Cytokines - metabolism | Coculture Techniques | Humans | Cells, Cultured | Endothelium, Vascular - drug effects | Monocytes - metabolism | Monocytes - immunology | Cell Adhesion - drug effects | Hypolipidemic Agents - pharmacology | Simvastatin - pharmacology | Monocytes - drug effects | Enalapril - pharmacology | Endothelium, Vascular - metabolism | U937 Cells | Anticoagulants - pharmacology | Interleukin-10 - metabolism | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Thromboplastin - metabolism | Interleukin-6 - metabolism | Endothelium, Vascular - immunology | Thromboplastin/metabolism | Anticoagulants/pharmacology | Antilipemic Agents/pharmacology | Cell Adhesion/drug effects | Cells; Cultured | Simvastatin/pharmacology | Angiotensin-Converting Enzyme Inhibitors/pharmacology | Tedelparin/pharmacology | Tumor Necrosis Factor-alpha/metabolism | Interleukin-6/metabolism | Enalapril/pharmacology | Research Support; Non-U.S. Gov't | Cytokines/metabolism | Endothelium; Vascular/drug effects/immunology/metabolism | Monocytes/drug effects/immunology/metabolism | Interleukin-10/metabolism
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 2009, Volume 133, Issue 3, pp. 185 - 190
The purpose of this study was to provide a culture method for an effective expansion of human CD 34 positive hematopoietic progenitor cells (CD 34 (+) HCs)... 
Cell proliferation | Controlled drug release | Low molecular weight heparin/protamine microparticles (LH/P MPs) | CD 34 positive hematopoietic progenitor cells (CD 34 (+) HCs) | Cytokine | STEM-CELLS | BONE-MARROW | CONTROLLED-RELEASE | CHEMISTRY, MULTIDISCIPLINARY | HYDROGEL | EX-VIVO EXPANSION | FIBROBLAST GROWTH FACTOR-2 | VASCULARIZATION | PROTAMINE | GM-CSF | PHARMACOLOGY & PHARMACY | HEPARAN-SULFATE | Antigens, CD34 - analysis | Molecular Weight | Humans | Delayed-Action Preparations - chemistry | Membrane Proteins - pharmacology | Glycosaminoglycans - chemistry | Cell Culture Techniques - methods | Cytokines - chemistry | Microspheres | Delayed-Action Preparations - pharmacology | Stem Cell Factor - pharmacology | Dalteparin - chemistry | Culture Media - chemistry | Thrombopoietin - chemistry | Binding, Competitive | Hematopoietic Stem Cells - drug effects | Protamines - chemistry | Cell Culture Techniques - instrumentation | Enzyme-Linked Immunosorbent Assay | Hematopoietic Stem Cells - metabolism | Stem Cell Factor - chemistry | Thrombopoietin - pharmacology | Antigens, CD34 - blood | Particle Size | Membrane Proteins - chemistry | Hematopoietic Stem Cells - cytology | Culture Media - pharmacology | Cell Proliferation - drug effects | Kinetics | Cytokines - pharmacology | Heparin - chemistry | Legislators | Somatotropin | Surgery, Plastic | Universities and colleges | Growth factors | Stem cells
Journal Article
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 12/2010, Volume 104, Issue 6, pp. 1242 - 1249
AZD0837, currently in clinical development, is a once-daily oral anticoagulant that is bioconverted to AR-H067637, a selective, reversible direct thrombin... 
direct thrombin inhibitor | bleeding | rat | venous and arterial thrombosis | AR-H067637 | Animal Models | Venous and arterial thrombosis | Rat | Bleeding | Direct thrombin inhibitor | XIMELAGATRAN | PREVENTION | TIME | PHARMACODYNAMICS | STROKE | DABIGATRAN | PHARMACOKINETICS | ORAL DIRECT THROMBIN | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | FACTOR XA INHIBITOR | SYSTEMIC EMBOLISM | Prodrugs - administration & dosage | Thrombosis - chemically induced | Venous Thrombosis - chemically induced | Thrombin - antagonists & inhibitors | Venous Thrombosis - blood | Male | Antithrombins - administration & dosage | Azetidines - pharmacology | Azetidines - toxicity | Antithrombins - pharmacology | Dose-Response Relationship, Drug | Peptide Hydrolases - blood | Antithrombin III | Chlorides | Venous Thrombosis - prevention & control | Thrombosis - blood | Thrombosis - prevention & control | Disease Models, Animal | Thrombin Time | Dalteparin - pharmacology | Antithrombins - toxicity | Amidines - toxicity | Rats | Rats, Sprague-Dawley | Ferric Compounds | Fibrinolytic Agents - pharmacology | Animals | Azetidines - administration & dosage | Amidines - administration & dosage | Blood Coagulation - drug effects | Partial Thromboplastin Time | Prodrugs - toxicity | Amidines - pharmacology | Fibrinolytic Agents - administration & dosage | Fibrinolytic Agents - toxicity | Hemorrhage - chemically induced | Infusions, Intravenous | Thrombin - metabolism | Prodrugs - pharmacology
Journal Article
Journal Article